Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ASPH | Q12797 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18370671 | 0.84 | ABL1 (0.57) | ABL1SRC | |
| SCHEMBL30147636 | 0.84 | PKM (0.48) | AGBL2ABL1SRCPOLBPKM | |
| SCHEMBL833129 | 0.79 | ABL1 (0.47) | ABL1SRCPOLBALDH1A1HPGD | |
| SCHEMBL297192 | 0.79 | KDM4E (0.51) | DAOABL1SRCCYP2C19ALDH1A1 | |
| SCHEMBL31296111 | 0.77 | SMAD3 (0.50) | DAOABL1SRCCYP2C19CYP2C9 | |
| SCHEMBL1098911 | 0.76 | FFAR1 (0.44) | AGBL2CYP2C9ALDH1A1GAAKDM4E | |
| SCHEMBL13625358 | 0.76 | PIN1 (0.51) | DAOABL1SRCHPGDKDM4E | |
| SCHEMBL15738800 | 0.76 | DAO (0.45) | DAOABL1SRCPOLBPKM | |
| SCHEMBL2106960 | 0.76 | F7 (0.56) | DAOABL1SRCCYP2C19CYP2C9 | |
| SCHEMBL16592793 | 0.76 | TSHR (0.46) | DAOABL1SRCCYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| CN-117430606-A | Sulfonamide PARP7 inhibitors | 山东轩竹医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117396485-A | PARP7 inhibitors | 轩竹生物科技股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| WO-2022247839-A1 | PARP7 INHIBITOR | 山东轩竹医药科技有限公司 | 2022-12-01 | — | — | WO | disclosed |
| WO-2021229302-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-11-18 | — | — | WO | disclosed |
| US-10308637-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-06-04 | — | — | US | disclosed |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10023557-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-07-17 | — | — | US | disclosed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| CN-101772499-A | Tricyclic N-heteroaryl-carboxamide derivatives, their preparation and their therapeutic use | SANOFIS AVENTIS | 2010-07-07 | — | — | CN | disclosed |
| EP-1987010-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2010-04-07 | — | — | EP | disclosed |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-1912644-B1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| WO-2009112678-A2 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| EP-1987010-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| CN-101247808-A | N- (arylalkyl) -1H-pyrrolopyridine-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2008-08-20 | — | — | CN | disclosed |
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
| WO-2007088277-A1 | TRICYCLIC Ν-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DAO 2963/4885AGBL2 273/4885ABL1 878/4885 |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DAO 2963/4885AGBL2 273/4885ABL1 878/4885 |
| US-20080125459-A1 | N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP3A5, ZYX, ZDHHC2 | DAO 2524/4885AGBL2 2587/4885ABL1 15/4885 |
| US-10023557-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DAO 2963/4885AGBL2 273/4885ABL1 878/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | DAO 69/4885AGBL2 2412/4885ABL1 931/4885 |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DAO 2963/4885AGBL2 273/4885ABL1 878/4885 |
| US-20090298865-A1 | Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof | PYCR1, ATP5PD, NQO2 | DAO 1117/4885AGBL2 2957/4885ABL1 24/4885 |
| US-20100041634-A1 | N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy | ZYX, NQO2, PYCR1 | DAO 313/4885AGBL2 2869/4885ABL1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.